HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Cohance Lifesciences Ltd Stock Comparison

Alivus Life Sciences Ltd vs Cohance Lifesciences Ltd Stock Comparison

Last Updated on: May 30, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1045 as of 30 May 15:30.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 years.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Suven Pharmaceuticals Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Suven Pharmaceuticals Ltd?

Market cap of Alivus Life Sciences Ltd is 12,814 Cr while Market cap of Suven Pharmaceuticals Ltd is 26,595 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Suven Pharmaceuticals Ltd?

The stock performance of Alivus Life Sciences Ltd and Suven Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Suven Pharmaceuticals Ltd?

As of May 30, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1045.0. On the other hand, Suven Pharmaceuticals Ltd stock price is INR ₹1044.75.

How do dividend payouts of Alivus Life Sciences Ltd and Suven Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Suven Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions